PRODUCT INFORMATION



Nimodipine

Item No. 14573

CAS Registry No.:	66085-59-4	
Formal Name:	1,4-dihydro-2,6-dimethyl-4-(3-	NO ₂
	nitrophenyl)-3,5-pyridinedicarboxylic acid,	
	3-(2-methoxyethyl) 5-(1-methylethyl) ester	
Synonym:	BAY-e 9736	
MF:	C ₂₁ H ₂₆ N ₂ O ₇	
FW:	418.4	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 237, 356 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	Ĥ
Stability:	≥4 years	
Information represents the product expections. Databased expection and tipel repute are provided on each certificate of each rise		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nimodipine is supplied as a crystalline solid. A stock solution may be made by dissolving the nimodipine in the solvent of choice, which should be purged with an inert gas. Nimodipine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of nimodipine in these solvents is approximately 2, 25, and 30 mg/ml, respectively.

Nimodipine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nimodipine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Nimodipine has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Nimodipine is an inhibitor of L-type voltage-gated calcium (Ca_V) channels.¹ It is selective for Ca_V1.2 over $Ca_v 1.3$ channels (IC₅₀s = 0.139 and 2.7 μ M, respectively), as well as R-, N-, and P/Q-type Ca_v channels at 10 µM.^{1,2} Nimodipine (0.72-24 nM) inhibits contractions induced by potassium, but not norepinephrine, in isolated rabbit aortic strips.³ It increases cerebral blood flow in anesthetized dogs when administered sublingually at doses ranging from 0.01 to 1 mg/kg. Nimodipine decreases necrosis of hippocampal CA1 pyramidal neurons and reduces increases in spontaneous movement and contralateral circling in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO).⁴

References

- 1. Furukawa, T., Yamakawa, T., Midera, T., et al. Selectivities of dihydropyridine derivatives in blocking Ca²⁺ channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 291(2), 464-473 (1999).
- 2. Xu, W. and Lipscombe, D. Neuronal $Ca_1 3a_1$ L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci. 21(16), 5944-5951 (2001).
- 3. Kazda, S. and Towart, R. Nimodipine: A new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir. (Wien) 63(1-4), 259-265 (1982).
- Babu, C.S. and Ramanathan, M. Post-ischemic administration of nimodipine following focal cerebral 4. ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergetics. Int. J. Dev. Neurosci. 29(1), 93-105 (2011).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM